SPPL3: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: SPPL3

NCBI ID: G121665

SPPL3

SPPL3: A Potential Drug Target for Cancer and Neurodegenerative Diseases

SPPL3 (SPPL3_HUMAN) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer. The gene is located on chromosome 6 and encodes for a protein known as sphingomyelin phosphorylase 3.

SPPL3 is a member of the SPPL3 gene family, which is characterized by the presence of a unique catalytic domain called P2. This domain is known to be involved in the regulation of various cellular processes, including cell signaling, inflammation, and metabolism.

One of the unique aspects of SPPL3 is its ability to interact with various signaling pathways, including the PI3K/Akt signaling pathway. This interaction allows SPPL3 to play a role in the regulation of cellular processes that are important for cancer progression, such as cell proliferation, migration, and invasion.

SPPL3 has also been shown to be involved in the regulation of inflammation. Studies have shown that SPPL3 can modulate the expression of genes involved in inflammation, including pro-inflammatory cytokines and enzymes involved in the production of reactive oxygen species (ROS). This suggests that SPPL3 may have a negative impact on the inflammatory response and may be a potential therapeutic target for the treatment of inflammatory diseases.

SPPL3 has also been shown to be involved in the regulation of cellular signaling pathways that are important for cancer progression. Studies have shown that SPPL3 can interact with genes involved in cell signaling, including the ERK1/2 signaling pathway. This interaction allows SPPL3 to play a role in the regulation of cellular processes that are important for cancer growth and progression.

In addition to its involvement in cellular signaling pathways, SPPL3 has also been shown to have potential as a drug target or biomarker in several disease models. For example, studies have shown that SPPL3 can be overexpressed in various cancer types, including breast cancer, lung cancer, and colon cancer. This increase in SPPL3 expression has been shown to lead to the development of various cellular and biological changes, including increased cell proliferation, migration, and invasion.

Furthermore, SPPL3 has also been shown to be involved in the regulation of cellular processes that are important for the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that SPPL3 can interact with genes involved in the production of neurotransmitters, including dopamine and Alzheimer's disease-related protein (APB), which are involved in the regulation of neural function and the development of neurodegenerative diseases.

In conclusion, SPPL3 is a gene that has the potential to be a drug target or biomarker for the treatment of various diseases. Its unique ability to interact with various signaling pathways, including the PI3K/Akt signaling pathway, makes it an attractive target for the development of new therapies. Furthermore, its involvement in the regulation of cellular processes that are important for cancer progression, inflammation, and neurodegenerative diseases makes it a promising candidate for the development of new therapeutic strategies.

Protein Name: Signal Peptide Peptidase Like 3

Functions: Intramembrane-cleaving aspartic protease (I-CLiP) that cleaves type II membrane protein substrates in or close to their luminal transmembrane domain boundaries (PubMed:16873890, PubMed:25354954, PubMed:25827571). Acts like a sheddase by mediating the proteolytic release and secretion of active site-containing ectodomains of glycan-modifiying glycosidase and glycosyltransferase enzymes such as MGAT5, B4GAT1 and B4GALT1 (PubMed:25354954, PubMed:25827571). Catalyzes the intramembrane cleavage of the envelope glycoprotein gp130 and/or the leader peptide gp18LP of the simian foamy virus independent of prior ectodomain shedding by furin or furin-like proprotein convertase (PC)-mediated cleavage proteolysis (PubMed:23132852). May also have the ability to serve as a shedding protease for subsequent intramembrane proteolysis by SPPL2A and SPPL2B of the envelope glycoprotein gp130 (PubMed:23132852). Plays a role in the regulation of cellular glycosylation processes (PubMed:25354954). Required to link T-cell antigen receptor (TCR) and calcineurin-NFAT signaling cascades in lymphocytes by promoting the association of STIM1 and ORAI1 during store-operated calcium entry (SOCE) in a protease-independent manner (PubMed:25384971)

The "SPPL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPPL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets